PTCT PTC Therapeutics, Inc.

8.45
0  -2%
Previous Close 8.64
Open 8.63
Price To book 2.47
Market Cap 288.73M
Shares 34,169,000
Volume 983,374
Short Ratio 5.85
Av. Daily Volume 1,205,870

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial initiated October 2016. Phase 3 part of trial to commence in 2017.
RG7916
Spinal Muscular Atrophy (SMA)
Received a Refusal to File letter for their NDA Filing - February 23 2016. Appeal rejected October 17, 2016. Decision made to resubmit NDA during 1Q 2017 under protest. New PDUFA date October 24, 2017.
Translarna
Duchenne muscular dystrophy caused by nonsense mutations (nmDMD)
Phase 3 data released March 2, 2017 - endpoints not met. Development to be discontinued.
Translarna
Nonsense mutation cystic fibrosis

Latest News

  1. Bernie Sanders thinks this $89,000-a-year drug should be $1,000 a year
  2. U.S. lawmakers seek pricing info on PTC Therapuetics' Duchenne drug
  3. PTC THERAPEUTICS, INC. Financials
  4. PTC Therapeutics, Inc. :PTCT-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
  5. PTC Therapeutics, Inc. :PTCT-US: Earnings Analysis: 2016 By the Numbers : March 21, 2017
  6. Knopp Biosciences Announces Election of Biotech Executive Shane Kovacs to Board of Managers
  7. Biotech Movers On Friday: Neurotrope Inc (NTRP) And PTC Therapeutics, Inc. (PTCT)
  8. Why PTC Therapeutics may have to lower the price on a $89,000-a-year drug it just bought
  9. Blog Coverage PTC Therapeutics Acquires Rights for Duchenne Muscular Dystrophy Drug from Marathon for $140 Million Upfront
  10. ($$) Marathon Sells Muscular-Dystrophy Drug to PTC After Pricing Scrutiny
  11. ($$) Marathon Sells Muscular-Dystrophy Drug to PTC After Pricing Scrutiny
  12. Why PTC Therapeutics, Tellurian, and B&G Foods Slumped Today
  13. PTC Therapeutics Buys Duchenne Drug for $140M
  14. Why PTC Therapeutics Stock Is Crashing Today
  15. ($$) Marathon Sells Muscular-Dystrophy Drug After Pricing Scrutiny
  16. Blasted for high price of old MD drug, Marathon sells rights
  17. Blasted for high price of old MD drug, Marathon sells rights
  18. Marathon Pharma sells $89,000 drug to N.J. company amid pricing criticism
  19. PTC Sticks Its Face in a Drug-Pricing Wasps' Nest
  20. Edited Transcript of PTCT earnings conference call or presentation 16-Mar-17 12:30pm GMT